Pacific Biosciences of California, Inc. (PACB) stock
PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
$1.96−0.01 (-0.51%)
Close on Nov 13, 2026Market cap $609.23MP/E –Yield 0.00%
Pacific Biosciences of California total assets
Total assets on the balance sheet at the end of each period.
Pacific Biosciences of California's total assets was $721.10M at Sep 30, 2026. For fiscal 2025 it was $784.08M, down 37.8% from the year before. Over ten years it grew 19.6% a year on average. The highest annual figure on record is $2.01B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $784.08M | -37.8% |
| FY2024 | Dec 31, 2024 | $1.26B | -27.8% |
| FY2023 | Dec 31, 2023 | $1.75B | -1.2% |
| FY2022 | Dec 31, 2022 | $1.77B | -12.0% |
| FY2021 | Dec 31, 2021 | $2.01B | +384.8% |
| FY2020 | Dec 31, 2020 | $413.98M | +179.7% |
| FY2019 | Dec 31, 2019 | $147.99M | -13.1% |
| FY2018 | Dec 31, 2018 | $170.28M | +18.2% |
| FY2017 | Dec 31, 2017 | $144.08M | +4.5% |
| FY2016 | Dec 31, 2016 | $137.88M | +5.2% |
| FY2015 | Dec 31, 2015 | $131.11M | +5.4% |
| FY2014 | Dec 31, 2014 | $124.39M | -8.7% |
| FY2013 | Dec 31, 2013 | $136.19M | +5.0% |
| FY2012 | Dec 31, 2012 | $129.68M | -40.6% |
| FY2011 | Dec 31, 2011 | $218.32M | -28.6% |
| FY2010 | Dec 31, 2010 | $305.75M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $721.10M | -10.2% |
| Q2 FY2026 | Jun 30, 2026 | $751.85M | -8.9% |
| Q1 FY2026 | Mar 31, 2026 | $782.37M | -9.1% |
| Q4 FY2025 | Dec 31, 2025 | $784.08M | -37.8% |
| Q3 FY2025 | Sep 30, 2025 | $803.16M | -44.6% |
| Q2 FY2025 | Jun 30, 2025 | $825.47M | -45.3% |
| Q1 FY2025 | Mar 31, 2025 | $860.79M | -48.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.26B | -27.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.45B | -23.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.51B | -18.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.67B | -11.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.75B | -1.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.90B | +4.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.85B | -1.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.90B | -2.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.77B | -12.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.82B | -10.6% |
| Q2 FY2022 | Jun 30, 2022 | $1.88B | +50.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.94B | +54.6% |
| Q4 FY2021 | Dec 31, 2021 | $2.01B | +384.8% |
| Q3 FY2021 | Sep 30, 2021 | $2.03B | +577.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.25B | +483.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.25B | +433.7% |
| Q4 FY2020 | Dec 31, 2020 | $413.98M | +179.7% |
| Q3 FY2020 | Sep 30, 2020 | $300.32M | +105.5% |
| Q2 FY2020 | Jun 30, 2020 | $213.65M | +25.2% |
| Q1 FY2020 | Mar 31, 2020 | $234.76M | +26.5% |
| Q4 FY2019 | Dec 31, 2019 | $147.99M | -13.1% |
| Q3 FY2019 | Sep 30, 2019 | $146.11M | -20.1% |
| Q2 FY2019 | Jun 30, 2019 | $170.58M | +24.5% |
| Q1 FY2019 | Mar 31, 2019 | $185.58M | +18.2% |
| Q4 FY2018 | Dec 31, 2018 | $170.28M | +18.2% |
| Q3 FY2018 | Sep 30, 2018 | $182.91M | +15.8% |
| Q2 FY2018 | Jun 30, 2018 | $137.06M | -23.0% |
| Q1 FY2018 | Mar 31, 2018 | $156.95M | +15.8% |
| Q4 FY2017 | Dec 31, 2017 | $144.08M | +4.5% |
| Q3 FY2017 | Sep 30, 2017 | $157.90M | – |
| Q2 FY2017 | Jun 30, 2017 | $177.91M | – |
| Q1 FY2017 | Mar 31, 2017 | $135.51M | – |
| Q4 FY2016 | Dec 31, 2016 | $137.88M | – |
See a number that looks wrong?